Rigel Pharmaceuticals, Inc. (RIGL) Social Stream

Featured Post From StockTwits About RIGL

$RIGL Let's not forget the NIH's wonderful research into NETosis, fostamatinib and C19.

NIH doctor discussing NETosis: "Some preliminary data suggests using a tyrosine kinase inhibitor (fostamatinib) we can fully reverse these phenotypes which is something that has us excited to study these implications moving forward."
https://www.youtube.com/watch?v=YcvJ2kEGOZ0
Lead investigator: Just out in JID, @dr_mjramos and I along with others show that R406 (fostamatinib) can inhibit NETs when neutrophils are stimulated with COVID-19 plasma.
https://twitter.com/JeffreyStrichMD/status/1342097212151648256
NIH lead study publication: This is the first report to identify that R406, a potent SYK inhibitor and the metabolically active component of fostamatinib, inhibits NETosis among healthy donor neutrophils stimulated with COVID-19 patient plasma.
https://academic.oup.com/jid/article/223/6/981/6046406

This, along with the inhibition of the cytokine storm and other hyper-inflammatory processes put us miles ahead of any other therapeutic for C19 and is why we'll get a EUA off an n=59.